Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects

被引：12

作者：

Al-Hamodi, Zaid ^{[1
]}

Saif-Ali, Riyadh ^{[1
,2
]}

Ismail, Ikram S. ^{[3
]}

Ahmed, Khaled A. ^{[4
]}

Muniandy, Sekaran ^{[1
]}

机构：

[1] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur 50603, Malaysia

[2] Fac Med, Dept Biochem, Sanaa, Yemen

[3] Univ Malaya, Med Ctr, Dept Med, Kuala Lumpur 50603, Malaysia

[4] Ibb Univ, Fac Dent, Ibb, Yemen

来源：

JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY | 2012年

关键词：

ANGIOTENSIN-CONVERTING ENZYME; 4G/5G POLYMORPHISM; GENE POLYMORPHISMS; METABOLIC SYNDROME; PROMOTER; 4G/5G; PAI-1; GENE; ASSOCIATION; RISK; FREQUENCY; GENOTYPE;

D O I：

10.1155/2012/234937

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Elevated activity of plasminogen activator inhibitor-1 (PAI-1) and decreased tissue plasminogen activator (tPA) activity are considered to be important risk factors for type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS). The aim of this study was to investigate the association of the PAI-1 4G/5G and tPA Alu-repeat I/D polymorphisms with T2DM in Malaysian subjects. Serum insulin, coronary risk panel, plasma glucose, and PAI-1 4G/5G and tPA Alu-repeat I/D polymorphisms were studied in 303 T2DM subjects (227 with MetS and 76 without MetS) and 131 normal subjects without diabetes and MetS. Statistical analysis showed that the dominant and additive models of PAI-1 4G/5G polymorphism showed a weak association with T2DM without MetS (OR = 2.35, P = 0.045; OR = 1.67, P = 0.058). On the other hand, the recessive model of the tPA Alu-repeat I/D polymorphism showed an association with T2DM with MetS (OR = 3.32, P = 0.013) whereas the dominant and additive models of the tPA Alu-repeat I/D polymorphism were not associated with T2DM either with or without MetS.

引用

页数：6

共 29 条

[1] Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction [J].

Ahmed, Waqas ;

Malik, Meera ;

Saeed, Imran ;

Khan, Amina Ali ;

Sadeque, Ahmed ;

Kaleem, Umar ;

Ahmed, Nuzhat ;

Ajmal, Muhammad ;

Azam, Maleeha ;

Qamar, Raheel .

MOLECULAR BIOLOGY REPORTS, 2011, 38 (04) :2541-2548

[2]

Al-Hamodi Z. H., J CLIN BIOC IN PRESS

[3] Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects [J].

Al-Hamodi, Zaid ;

Ismail, Ikram S. ;

Saif-Ali, Riyadh ;

Ahmed, Khaled A. ;

Muniandy, Sekaran .

CARDIOVASCULAR DIABETOLOGY, 2011, 10

[4] The metabolic syndrome - a new worldwide definition [J].

Alberti, KGMM ;

Zimmet, P ;

Shaw, J .

LANCET, 2005, 366 (9491) :1059-1062

[5] PAI-1 and the metabolic syndrome - Links, causes, and consequences [J].

Alessi, Marie-Christine ;

Juhan-Vague, Irene .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (10) :2200-2207

[6]

Anna, 2008, MECH EFFECTS LOW PLA

[7]

[Anonymous], 2006, Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation

[8] Genetic variation in promoter (4G/5G) of plasminogen activator inhibitor 1 gene in type 2 diabetes - Absence of relationship with microangiopathy [J].

Broch, M ;

Gutierrez, C ;

Aguilar, C ;

Simon, I ;

Richart, C ;

Vendrell, J .

DIABETES CARE, 1998, 21 (03) :463-463

[9] The metabolic syndrome [J].

Eckel, RH ;

Grundy, SM ;

Zimmet, PZ .

LANCET, 2005, 365 (9468) :1415-1428

[10] Diabetic retinopathy, PAI-1 4G/5G and-844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients [J].

Ezzidi, I. ;

Mtiraoui, N. ;

Chaieb, A. ;

Kacem, A. ;

Mahjoub, T. ;

Almawi, W. Y. .

DIABETES & METABOLISM, 2009, 35 (03) :214-219

← 1 2 3 →